San Francisco (AP) — Vaccine maker Movid Biotech says it has begun testing a vaccine that is designed to prevent the spread of polio in the United States, potentially helping to fight the virus.
Movid Biotechnology, based in California, said Friday it was testing the vaccine, called POLI-NEXT, which has been approved by the Food and Drug Administration for use in adults and children.
Polio is transmitted through coughing and sneezing.
The vaccine prevents the body’s immune system from attacking the virus, and is given to those who have already been infected with the virus and have died.
Poli-NXT is a synthetic protein, which makes it difficult for the body to attack the virus before it enters the bloodstream.
It works by blocking the virus from making copies of itself, which are then passed to the cells of the body.
It’s not clear how much the vaccine is likely to help prevent polio, but it would be an important step toward reducing the number of polio cases in the country.
In the U.S., about one in every 100 people infected with polio is still hospitalized, according to the Centers for Disease Control and Prevention.
The FDA has given approval for two other polio vaccines, Poli-SAR, made by the Pfizer Co. subsidiary, and PoliScan, made jointly by AstraZeneca and the Eli Lilly & Co. group.
The Pfizer vaccine has not been tested in the U, though Astra has.
In November, the FDA approved a third polio vaccine, Polio-6, made at Novartis AG and GlaxoSmithKline Plc.